标题：解毒固肾汤治疗血液透析患者对肾功能及血清LPO、PAI-1的影响

      作者：杨雪梅 1，张武 1，李文丽 2，闫建锋 2    1.安康市中医医院肾病—血液净化中心，陕西 安康 725000；2.安康市中医医院高新分院肾病—血液净化中心，陕西 安康 725000

      卷次： 2023年34卷14期

      【摘要】 目的 探讨解毒固肾汤治疗血液透析患者对其肾功能及血清脂质过氧化物(LPO)、纤溶酶原激活物抑制物-1 (PAI-1)的影响。方法 选择2019年1月至2022年1月在安康市中医医院肾病—血液净化中心行血液透析治疗的80例患者为研究对象，按随机数表法分为观察组和对照组各40例。对照组患者接受常规药物干预，观察组患者在对照组治疗的基础上联合解毒固肾汤治疗，两组患者均治疗3个月。比较两组患者的治疗效果，以及治疗前后的肾功能[胱抑素C (Cys-C)、血肌酐(Scr)、血尿素氮(BUN)]和血清LPO、PAI-1水平，同时比较两组患者治疗期间的不良反应发生情况。结果 观察组患者的治疗总有效率为97.50%，明显高于对照组的80.00%，差异有统计学意义(P<0.05)；治疗后，两组患者的Cys-C、Scr、BUN水平均降低，且观察组患者的Cys-C、Scr、BUN水平分别为(1.02±0.21) mg/L、(80.21±7.31) μmol/L、(6.21±1.12) mmol/L，明显低于对照组的(1.72±0.26) mg/L、(89.13±7.45) μmol/L、(8.91±1.32) mmol/L，差异均有统计学意义(P<0.05)；治疗后，两组患者的血清LPO、PAI-1水平均明显降低，且观察组患者的血清LPO、PAI-1水平分别为(7.21±1.13) nmol/L、(21.19±3.28) mg/L，明显低于对照组的(10.37±1.21) nmol/L、(24.91±3.31) mg/L，差异均有统计学意义(P<0.05)；观察组患者的不良反应发生率为 5.00%，略低于对照组的10.00%，但差异无统计学意义(P>0.05)。结论 解毒固肾汤治疗血液透析患者可改善其肾功能，调节血清LPO、PAI-1水平，临床应用效果好且安全性高。
      【关键词】 血液透析；解毒固肾汤；肾功能；脂质过氧化物；纤溶酶原激活物抑制物-1；疗效；不良反应
      【中图分类号】 R459.5 【文献标识码】 A 【文章编号】 1003—6350（2023）14—1982—04

Effect of Jiedu Gushen Decoction on renal function and serum LPO, PAI-1 in patients undergoing hemodialysis.YANG Xue-mei 1, ZHANG Wu 1, LI Wen-li 2, YAN Jian-feng 2.
1.Nephropathy—Blood Purification Center, AnkangTraditional Chinese Medicine Hospital, Ankang 725000, Shaanxi, CHINA; 2. Nephropathy—Blood Purification Center,Gaoxin Branch, Ankang Traditional Chinese Medicine Hospital, Ankang 725000, Shaanxi, CHINA
【Abstract】 Objective To investigate the effects of Jiedu Gushen Decoction on renal function, serum lipid per-oxide (LPO), and plasminogen activator inhibitor 1 (PAI-1) in patients undergoing hemodialysis. Methods Eighty pa-tients who underwent hemodialysis at the Nephropathy—Blood Purification Center, Ankang Traditional Chinese Medi-cine Hospital from January 2019 to January 2022 were selected as the research subjects. They were divided into an obser-vation group and a control group by random number table method, with 40 patients in each group. Patients in the controlgroup received routine drug intervention, while those in the observation group were treated with Jiedu Gushen Decoctionon the basis of the treatment in the control group, both for 3 months. The treatment effects of the two groups of patientswere compared, as well as the renal function [Cystatin C (Cys-C), serum creatinine (Scr), blood urea nitrogen (BUN)],serum LPO, PAI-1 levels before and after treatment, the incidence of adverse reactions during treatment was also com-pared between the two groups of patients. Results The total effective rate of treatment in the observation group was97.50%, significantly higher than 80.00% in the control group (P<0.05). After treatment, Cys-C, Scr, and BUN in thetwo groups decreased, and Cys-C, Scr, and BUN in the observation group were (1.02±0.21) mg/L, (80.21±7.31) μmol/L,(6.21±1.12) mmol/L, which were significantly lower than (1.72±0.26) mg/L, (89.13±7.45) μmol/L, (8.91±1.32) mmol/Lin the control group (P<0.05). After treatment, the levels of serum LPO and PAI-1 in both groups of patients were signif-icantly reduced, and the levels in the observation group were (7.21±1.13) nmol/L and (21.19±3.28) mg/L, which were sig-nificantly lower than (10.37±1.21) nmol/L and (24.91±3.31) mg/L in the control group (P<0.05). The incidence of adversereactions in the observation group was 5.00%, slightly lower than 10.00% in the control group (P>0.05). Conclusion Jie-du Gushen Decoction can improve renal function and regulate serum LPO and PAI-1 levels in patients undergoing hemo-dialysis, with good clinical application effect and high safety.
      【Key words】 Hemodialysis; Jiedu Gushen Decoction; Renal function; Lipid peroxide; Plasminogen activator in-hibitor-1; Efficacy; Adverse reactions